The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

HIMS BREAKING NEWS: Hims & Hers Health, Inc. is being Investigated for Securities Fraud; Investors with Losses are Notified to Contact BFA Law

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential violations of the federal securities laws.

If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action.

Why is Hims & Hers being Investigated?

Hims & Hers is a telehealth company that provides consumers access to online consultations with licensed healthcare professionals, prescription medications, and a range of wellness products. On April 29, 2025, Hims & Hers and Novo Nordisk announced a “long-term collaboration” through which Hims & Hers would sell Novo Nordisk’s popular weight loss drug Wegovy.

The Stock Declines as the Truth is Revealed

On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, accusing Hims & Hers of engaging in “deceptive marketing” and the illegal “selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” On this news, the price of Hims & Hers stock fell $22.25 per share, or more than 34%, from $64.22 per share on June 20, 2025 to $41.97 per share on June 23, 2025.

Click here for more information: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action.

What Can You Do?

If you invested in Hims & Hers you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action

Attorney advertising. Past results do not guarantee future outcomes.

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential violations of the federal securities laws.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.